electroCore (ECOR) Q3 2024 earnings summary

Executive summary

• Achieved eighth consecutive record quarterly revenue of $6.6 million in Q3 2024, up 45% year-over-year, with year-to-date revenue reaching $18.1 million, a 67% increase over the first nine months of 2023.

• Net loss for Q3 2024 narrowed to $2.5 million from $4.0 million in Q3 2023, reflecting higher sales and reduced R&D spending.

• Majority of revenue continues to come from VA/DoD channels, with ongoing expansion in government and commercial markets.

• Company expects to fund operations for at least 12 months based on current cash position and reduced net loss.

• Expanded product lines in both prescription and non-prescription wellness markets, including Truvaga Plus.

Financial highlights

• Q3 2024 net sales were $6.6 million, up from $4.5 million in Q3 2023; nine-month sales totaled $18.1 million, up 67% year-over-year.

• Gross profit for Q3 2024 was $5.5 million, with gross margin stable at 84%.

• GAAP net loss for Q3 2024 was $2.5 million ($0.31/share), improved from $4 million ($0.68/share) in Q3 2023.

• Adjusted EBITDA net loss improved to $2.1 million in Q3 2024 from $3.0 million in Q3 2023.

• Cash, cash equivalents, and marketable securities totaled $13.2 million as of September 30, 2024.

Outlook and guidance

• Management expects continued sequential decline in cash used in operations and Adjusted EBITDA loss as revenue increases.

• Anticipate positive cash flow from operations early next year, with operating leverage supporting a path to profitability.

• Majority of 2024 revenue expected from VA/DoD; TAC-STIM product revenue may fluctuate quarter to quarter.

• No formal top-line guidance provided, but internal review of guidance policy is ongoing.

• Ongoing investments planned in sales and marketing to support commercial growth.